Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status

Detalles Bibliográficos
Autores principales: Rizvi, Naiyer, Chaft, Jamie, Balmanoukian, Ani, Goldberg, Sarah B, Sanborn, Rachel E, Steele, Keith E, Rebelatto, Marlon C, Gu, Yu, Karakunnel, Joyson J, Antonia, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649434/
http://dx.doi.org/10.1186/2051-1426-3-S2-P193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649434/
http://dx.doi.org/10.1186/2051-1426-3-S2-P193

Ejemplares similares